IMPROVEMENT
AT WEEK 24
with DUPIXENT vs 1% improvement with
placebo in SINUS-52 (P<0.0001)2,a
CONTINUED IMPROVEMENT
AT WEEK 52
with DUPIXENT vs 2% worsening with
placebo in SINUS-522,b
(analysis of change at Week 52 was not multiplicity controlled;
result is descriptive)
aWeek 24 in SINUS-52 (key secondary endpoint). LSM difference between DUPIXENT 300 mg Q2W + INCS (n=295, pooled DUPIXENT arms) vs placebo + INCS (n=153): -5.13 (95% CI: -5.80, -4.46) (-5.2 from a baseline score of 18.12 vs -0.09 from a baseline score of 17.65, respectively).2
b Week 52 in SINUS-52 (other secondary endpoint). LSM difference between DUPIXENT 300 mg Q2W + INCS (n=150) vs placebo + INCS (n=153): -6.94 (95% CI: -7.87, 6.01) (-6.83 from a baseline score of 18.42 vs 0.11 from a baseline score of 17.65, respectively).2
DUPIXENT is the only approved
biologic in CRSwNP that evaluated
changes in LMK‑CT scores in
pivotal trials (SINUS-24 and
SINUS-52)1
SEE THE SCAN FROM A REAL DUPIXENT PATIENT
to see results
![](/dam/jcr:85686a84-ef25-4e7c-b9c8-54da4fe82842/before.jpg)
![](/dam/jcr:daf397de-d0b8-4753-806d-b29d4bbe163f/before-mob.png)
![](/dam/jcr:f306f343-0acc-4ef8-a02d-a9d758fb66d5/after.png)
![](/dam/jcr:40eefe7b-9dfe-4364-b02b-01a77de993a9/after-mob.png)
CT scan of patient from clinical trial. Individual results may vary.
DUPIXENT demonstrated statistically significant reductions in
opacification across all individual sinuses at Week 242
Lund-Mackay computed tomography (LMK-CT) score (range 0 to 24): reduced score indicates improvement.1
CI, confidence interval; INCS, intranasal corticosteroid; LSM, least squares mean; Q2W, once every 2 weeks.
Explore the Safety Data and Study Designs
Dosage and
Administration
See the recommended dosing and administration options for patients on DUPIXENT.